The Clinically Active PARP Inhibitor Olaparib Ameliorates Doxorubicin-induced Cardiotoxicity in Both Invitro and In-vivo Model

Inhibition of poly-ADP-ribose-polymerase (PARP) has been shown to be cardioprotective in acute and chronic myocardial injury. Additionally, activation of the PARP pathway was also suggested to be involved in doxorubicin-induced cardiotoxicity (DIC). In this study, we used clinically available anti-cancer PARP inhibitor Olaparib to determine the cardioprotective effects in preventing DIC in in vitro and in vivo models.